KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Inventory: 2018-2025

Historic Inventory for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $8.7 million.

  • Castle Biosciences' Inventory rose 31.62% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 31.62%. This contributed to the annual value of $8.1 million for FY2024, which is 2.43% up from last year.
  • Per Castle Biosciences' latest filing, its Inventory stood at $8.7 million for Q3 2025, which was up 3.39% from $8.4 million recorded in Q2 2025.
  • Castle Biosciences' Inventory's 5-year high stood at $8.7 million during Q3 2025, with a 5-year trough of $2.0 million in Q4 2021.
  • Its 3-year average for Inventory is $7.1 million, with a median of $7.6 million in 2024.
  • Per our database at Business Quant, Castle Biosciences' Inventory spiked by 99.55% in 2023 and then declined by 10.41% in 2025.
  • Castle Biosciences' Inventory (Quarterly) stood at $2.0 million in 2021, then soared by 96.93% to $4.0 million in 2022, then surged by 99.55% to $7.9 million in 2023, then increased by 2.43% to $8.1 million in 2024, then surged by 31.62% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $8.4 million for Q2 2025, and $6.8 million during Q1 2025.